磷酸化原癌基因酪氨酸蛋白激酶受体RET抗体

本公司是最专业磷酸化原癌基因酪氨酸蛋白激酶受体RET抗体供应商，提供磷酸化原癌基因酪氨酸蛋白激酶受体RET抗体的报价，泛素样蛋白Sumo2/3抗体咨询，

英文名称  Anti-phospho-Ret/HSCR1(Tyr1062)

中文名称  磷酸化原癌基因酪氨酸蛋白激酶受体RET抗体

别    名  Ret (phospho Y1062); p-Ret(phospho Y1062); C ret; Cadherin family member 12; CDHF 12; CDHF12; ELKS Fusion gene; HSCR 1; HSCR1; Hydroxyaryl protein kinase; MEN2A; MEN2B; MTC 1; MTC1; Multiple endocrine neoplasia and medullary thyroid carcinoma 1; Oncogene RET; Proto oncogene tyrosine protein kinase receptor ret; Proto-oncogene c-Ret; Proto-oncogene tyrosine-protein kinase receptor ret; PTC; RET; RET ELE1; Ret Proto oncogene; RET transforming sequence; RET_HUMAN; RET51.

浓    度  1mg/1ml

规 格  0.1ml/200μg

磷酸化原癌基因酪氨酸蛋白激酶受体RET抗体概述：

B淋巴细胞在抗原的刺激下，能够分化、增殖形成具有针对这种抗原分泌特异性抗体的能力。B细胞的这种能力和量是有限的，不可能持续分化增殖下去，因此产生免疫球蛋白的能力也是极其微小的。将这种B细胞与非分泌型的骨髓瘤细胞融合形成杂交瘤细胞，再进一步克隆化，这种克隆化的杂交瘤细胞是既具有瘤细胞的无限分裂的能力，又具有产生特异性抗体的B淋巴细胞的能力。将这种克隆化的杂交瘤细胞进行培养或注入小鼠腹水内即可获得大量的高效、单一的特异性抗体。这种技术即称为单克隆抗体技术。

抗体来源  Rabbit  

克隆类型  polyclonal

交叉反应  Human, Mouse, Rat  

产品类型  一抗  磷酸化抗体  

研究领域  肿瘤 细胞生物 信号转导 生长因子和激素 激酶和磷酸酶  

蛋白分子量  predicted molecular weight: 119kDa

性    状  Lyophilized or Liquid

免 疫 原  KLH conjugated Synthesised phosphopeptide derived from human Ret around the phosphorylation site of Tyr1062

亚    型  IgG

纯化方法  affinity purified by Protein A

储 存 液  Preservative: 15mM Sodium Azide, Constituents: 1% BSA, 0.01M PBS, pH 7.4

产品应用   WB=1:100-500  ELISA=1:500-1000  IP=1:20-100  IHC-P=1:100-500  IHC-F=1:100-500  ICC=1:100-500  IF=1:100-500

（石蜡切片需做抗原修复）

 not yet tested in other applications.

 optimal dilutions/concentrations should be determined by the end user.  

保存条件  Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C.

Important Note  This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.

产品介绍 Probable receptor with tyrosine-protein kinase activity; important for development.

Subunit : Phosphorylated form interacts with the PBT domain of DOK2, DOK4 and DOK5. The phosphorylated form interacts with PLCG1 and GRB7 (By similarity). Interacts (not phosphorylated) with CC PTK2/FAK1 (via FERM domain). Extracellular cell-membrane anchored RET cadherin fragments form complex in neurons with reduced trophic status, preferentially at the contact sites between somas. Interacts with AIP in the pituitary gland; this interaction prevents the formation of the AIP-survivin complex. Binds to ARTN.

Subcellular Location : Cell membrane; Single-pass type I membrane protein. Endosome membrane; Single-pass type I membrane protein.

Post-translational modifications : Autophosphorylated on C-terminal tyrosine residues upon ligand stimulation. Dephosphorylated by PTPRJ on Tyr-905, Tyr-1015 and Tyr-1062.

Proteolytically cleaved by caspase-3. The soluble RET kinase fragment is able to induce cell death. The extracellular cell-membrane anchored RET cadherin fragment accelerates cell adhesion in sympathetic neurons.

DISEASE : Defects in RET may be a cause of colorectal cancer (CRC) [MIM:114500].

Defects in RET are a cause of Hirschsprung disease type 1 (HSCR1) [MIM:142623]. HSCR1 is a disorder of neural crest development characterized by the absence of intramural ganglion cells in the myenteric and submucosal plexuses of the gastrointestinal tract, often resulting in intestinal obstruction. Total colonic aganglionosis and total intestinal Hirschsprung disease also occur. Occasionally, MEN2A or FMTC occur in association with HSCR1.

磷酸化原癌基因酪氨酸蛋白激酶受体RET抗体Similarity : Belongs to the protein kinase superfamily. Tyr protein kinase family.

Contains 1 cadherin domain.

Contains 1 protein kinase domain.